Trial · NCT00824265
Adverse events486
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 486
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 24 | 181 | |
| other | Anaemia | Blood and lymphatic system disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 38 | 178 | |
| other | Leukopenia | Blood and lymphatic system disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 27 | 181 | |
| other | Leukopenia | Blood and lymphatic system disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 10 | 178 | |
| other | Neutropenia | Blood and lymphatic system disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 93 | 181 | |
| other | Neutropenia | Blood and lymphatic system disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 62 | 178 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 38 | 181 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 55 | 178 | |
| other | Constipation | Gastrointestinal disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 8 | 181 | |
| other | Constipation | Gastrointestinal disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 11 | 178 | |
| other | Diarrhoea | Gastrointestinal disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 14 | 181 | |
| other | Diarrhoea | Gastrointestinal disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 19 | 178 | |
| other | Nausea | Gastrointestinal disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 45 | 181 | |
| other | Nausea | Gastrointestinal disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 36 | 178 | |
| other | Vomiting | Gastrointestinal disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 19 | 181 | |
| other | Vomiting | Gastrointestinal disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 22 | 178 | |
| other | Asthenia | General disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 13 | 181 | |
| other | Asthenia | General disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 16 | 178 | |
| other | Chills | General disorders | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 14 | 181 | |
| other | Chills | General disorders | Fludarabine + Cyclophosphamide_ ITT Subjects | 3 | 178 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00824265/events